Soros Fund Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Soros Fund Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-105,500	Closed	-$6.4M	–	310
2015 Q1	$6.4M	Buy	105,500 +80,000	+314%	+$3.88M	0.06%	154
2014 Q4	$1.33M	Buy	+25,500	New	+$1.14M	0.01%	171

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Soros Fund Management's JUNO Position: Q2 2015 in Review

Soros Fund Management sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2015, closing a stake of 105,500 shares — an estimated $6.4M sold.

Soros Fund Management first reported a position in JUNO in Q4 2014 and held it in 2 quarters. The position peaked at $6.4M in Q1 2015. 154 funds tracked by Wall St. Rank hold JUNO as of Q2 2015.

Soros Fund Management reported no remaining Juno Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Soros Fund Management sold 105,500 Juno Therapeutics, Inc. shares in Q2 2015, an estimated $6.4M.
Soros Fund Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
Soros Fund Management's Juno Therapeutics, Inc. position peaked at $6.4M in Q1 2015.
154 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2015.

Based on Soros Fund Management's 13F filing for Q2 2015, filed 14 Aug 2015.